Critical design criteria for engineering a nanoparticulate HIV-1 vaccine.
HIV-1/AIDS
Lymph node distribution
Multivalence, Envelope glycoprotein (Env)
Nanoparticles
Vaccine delivery
Journal
Journal of controlled release : official journal of the Controlled Release Society
ISSN: 1873-4995
Titre abrégé: J Control Release
Pays: Netherlands
ID NLM: 8607908
Informations de publication
Date de publication:
10 01 2020
10 01 2020
Historique:
received:
08
10
2019
revised:
26
11
2019
accepted:
27
11
2019
pubmed:
2
12
2019
medline:
22
6
2021
entrez:
2
12
2019
Statut:
ppublish
Résumé
Inducing a long-lasting as well as broad and potent immune response by generating broadly neutralizing antibodies is a major goal and at the same time the main challenge of preventive HIV-1 vaccine design. Immunization with soluble, stabilized and native-like envelope (Env) glycoprotein so far only led to low neutralization breadth and displayed low immunogenicity. A promising approach to generate a potent immune response is the presentation of Env on the surface of nanoparticles. In this review, we will focus on two key processes essential for the induction of immune response that can be addressed by specific features of nanoparticulate carriers: first, the trafficking to and within distinct compartments of the lymph node, and second, the use of multivalent Env display allowing for high avidity interactions. To optimize these pivotal steps critical design criteria should be considered for the presentation of Env on nanoparticles. These include an optimal particle size below 100 nm, distances between two adjacent Env antigens of approximately 10-15 nm, an appropriate orientation of Env, and finally, the stability of both the Env attachment and the nanoparticle platform. Hence, an interdisciplinary approach that combines a suitable delivery system and a straightforward presentation of the Env antigen may have the potential to drive the immune response towards increased breadth and potency.
Identifiants
pubmed: 31786187
pii: S0168-3659(19)30704-7
doi: 10.1016/j.jconrel.2019.11.035
pii:
doi:
Substances chimiques
AIDS Vaccines
0
Antibodies, Neutralizing
0
HIV Antibodies
0
env Gene Products, Human Immunodeficiency Virus
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
322-335Informations de copyright
Copyright © 2019. Published by Elsevier B.V.